Posts by B-BIC

NEW AWARD: CONGRATULATIONS DR. NELSON RUIZ – OPAZO

RECIPIENT:  Dr. Nelson Ruiz – Opazo TITLE: Fully humanized anti-DEpR antibody therapy for acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) TYPE OF AWARD:  PILOT TECHNOLOGY TYPE: Biologic Drug CLINICAL AREA: Lung INDICATION: Acute Lung Injury / Acute Respiratory Distress Syndrome INSTITUTION: Boston University DESCRIPTION:The feed-forward progression of acute lung injury (ALI) towards acute respiratory distress syndrome (ARDS)…

Read More

Tips & Tricks:  Writing your B-BIC Proposal or Business Plan Overview

The best way to begin an overview is by presenting a clear picture of the problem that needs to be solved.  Aim to tell a narrative story about the specific problem that patients or clinicians are currently experiencing. Address a specific disease or healthcare management issue, and include key facts to show the potential market size. Define…

Read More

Specialist Series: How to build an effective overview of your technology.

Contributed by Erin McKenna, B-BIC Deputy Director After the dip in investment in early-stage biotechnology in 2008, the number of funding opportunities for early-stage technologies has been increasing in recent years. Despite this promising trend, finding and securing the funding necessary to move your research out of the lab and towards commercialization is still a…

Read More

NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges

Commercializing innovations in academic environments is notoriously challenging. Here, we describe the progress of the NIH Centers for Accelerated Innovations program — initiated in 2013 to address these challenges — which we believe could help set a new standard for the early-stage commercialization of biomedical innovations in academic environments. Read More On Nature.com.

Read More

Specialist Series: Reimbursement

If reimbursement is so important … why do so many companies address it so half-heartedly and so late? Edward E. Berger, Ph.D. Everyone knows how important reimbursement analysis and planning is to the success of innovative medical technology and life science products.  Ask any venture capitalist, private equity investor, strategic marketing analyst, or C-level executive;…

Read More

NEW AWARD: CONGRATULATIONS DR. LEO TSAI!

RECIPIENT: Dr. Leo Tsai TITLE: A Novel Coaxial Deflectable Microcatheter for Rapid Navigation of Tortuous Vessels TYPE OF AWARD: DRIVE INSTITUTION: Beth Israel Deaconess Medical Center TECHNOLOGY TYPE: Therapeutic Device DESCRIPTION: Microcatheters are used to access small vessels throughout the body to treat a wide variety of pathology, from traumatic hemorrhage to tumors. Selection of…

Read More

Bringing the Immunity-to-Change™ process to the scientific community

Community member post by Erica Lawlor and Cheryl Vaughan How can scientists whose careers were formed in an incentive system that cultivates competitive and territorial behaviors be helped to meet the expectations of collaborative research frameworks? A team-based approach that transcends disciplinary boundaries may be a tall order for scientists who “grew up” in a…

Read More

Specialist Series: Your Elevator Pitch: Don’t leave home without it!

Written by Melissa Marshall Have you ever walked away from a conversation about your work with an important individual and thought, “Darn. I wish I would have explained that better or said it this way instead…”? Or maybe you had an unexpected interaction with someone who asked about your work and you just started rambling…

Read More

NEW AWARD: CONGRATULATIONS DR. BEN MATTHEWS

RECIPIENT:  Dr. Ben Matthews TITLE: PR1P, an inhaled novel short peptide for emphysema TYPE OF AWARD:  PILOT INSTITUTION: Boston Children’s Hospital DESCRIPTION:  Emphysema is a chronic progressive pulmonary disease characterized by destruction of alveoli leading to impaired lung function that threatens human health worldwide. Disease progression is due in part to dysregulation of the survival factor Vascular Endothelial Growth Factor (VEGF). …

Read More

Specialist Series: Patents

What is a U.S. patent? A patent is a property right. The property right granted is an exclusionary right, i.e., the right to exclude others from making, using, offering for sale, or selling an invention. In the US, generally this exclusionary right lasts for 20 years from the date of the initial filing of an…

Read More